Thomas H. Adams, Ph.D. | Chief Executive Officer and Chairman
Dr. Adams has been our Chairman of the Board since April 2009 and Chief Executive Officer since June 2018. Dr. Adams served as the Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company from April 2013 to June 2017. From June 2005 through 2011, Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and has served as Chief Technology Officer of IRIS since April 2006. Dr. Adams was the Head of Iris Molecular Diagnostics from 2006 until November 2012 and has served as the President of IRIS Personalized Medicine since 2011. In November 2012, IRIS was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams was Chairman of Genta-Jago, a controlled release-based drug delivery company, from 1992 until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams was Chief Technology Officer of Hybratech, Inc., which focused on monoclonal antibody-based diagnostics and therapeutics, from 1980 to 1984. Dr. Adams has served as a Director of ContraVir Pharmaceuticals and Synergy Pharmaceuticals since September 2016. Dr. Adams served as a Director of Advanced Molecular Evolution, an antibody therapeutics company from 1991 until 2000. Dr. Adams served as a Director of Biosite, Inc., an antibody-based diagnostic company, from 1990 until 2000. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside. The Board believes that Dr. Adam’s executive leadership in therapeutic and diagnostic fields, as well as the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a Director of our Company.